Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Norman

Showing results (31-40 of 84) with videos related to

Pageof 9
Sort By:
Idrugs : the Investigational Drugs Journal|June 16, 2004
Medicinal chemistry in Eastern England -- 15th symposiumPeter Norman
Idrugs : the Investigational Drugs Journal|May 21, 2005
Medicinal Chemistry in Eastern England--16th SymposiumPeter Norman
Expert Opinion on Therapeutic Patents|January 17, 2013
Evaluation of WO2012080456 and WO2012080457; Boheringer Ingleheim's first CXCR2 antagonistsPeter Norman
Idrugs : the Investigational Drugs Journal|May 10, 2007
Fragments 2007--what has fragment-based drug discovery delivered for medicinal chemistry? 7 March 2007, Cambridge, UKPeter Norman
Expert Opinion on Therapeutic Patents|February 11, 2010
Long-acting muscarinic M3 receptor antagonistsPeter Norman
Expert Opinion on Therapeutic Patents|February 11, 2010
Long-acting muscarinic M3 receptor antagonistsPeter Norman
Expert Opinion on Therapeutic Patents|November 23, 2013
Evaluation of WO-2013040863, WO-2013041042 and WO-2013043962. Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffoldPeter Norman
Pharmaceutical Patent Analyst|February 17, 2017
Enbrel and etanercept biosimilars: a tale of two patent systemsPeter Norman
Idrugs : the Investigational Drugs Journal|December 23, 2003
Drugs from natural products - Third Annual MeetingPeter Norman
Current Opinion in Investigational Drugs (London, England : 2000)|April 22, 2006
Mecasermin TercicaPeter Norman
Pageof 9

Showing results (31-40 of 84) with videos related to

Sort By:
Pageof 9
Idrugs : the Investigational Drugs Journal|June 16, 2004
Medicinal chemistry in Eastern England -- 15th symposiumPeter Norman
Idrugs : the Investigational Drugs Journal|May 21, 2005
Medicinal Chemistry in Eastern England--16th SymposiumPeter Norman
Expert Opinion on Therapeutic Patents|January 17, 2013
Evaluation of WO2012080456 and WO2012080457; Boheringer Ingleheim's first CXCR2 antagonistsPeter Norman
Idrugs : the Investigational Drugs Journal|May 10, 2007
Fragments 2007--what has fragment-based drug discovery delivered for medicinal chemistry? 7 March 2007, Cambridge, UKPeter Norman
Expert Opinion on Therapeutic Patents|February 11, 2010
Long-acting muscarinic M3 receptor antagonistsPeter Norman
Expert Opinion on Therapeutic Patents|February 11, 2010
Long-acting muscarinic M3 receptor antagonistsPeter Norman
Expert Opinion on Therapeutic Patents|November 23, 2013
Evaluation of WO-2013040863, WO-2013041042 and WO-2013043962. Selective JAK1 inhibitors based on a 3-aminopyrazole-4-carboxamide scaffoldPeter Norman
Pharmaceutical Patent Analyst|February 17, 2017
Enbrel and etanercept biosimilars: a tale of two patent systemsPeter Norman
Idrugs : the Investigational Drugs Journal|December 23, 2003
Drugs from natural products - Third Annual MeetingPeter Norman
Current Opinion in Investigational Drugs (London, England : 2000)|April 22, 2006
Mecasermin TercicaPeter Norman
Pageof 9